REN and hydrops fetalis: Regarding HF treatments at baseline, 90.6% received diuretics, 85.5% a renin-angiotensin system inhibitor (36.7% received an angiotensin-converting enzyme inhibitor, 23.8% an angiotensin II receptor blocker, and 25.0% sacubitril/valsartan), 79.7% a beta blocker, 51.4% an aldosterone antagonist, 23.0% digoxin, and 3.1% ivabradine.